Oncopeptides (Sweden) Today

ONCO Stock  SEK 5.28  1.38  20.72%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Over 84

 
100  
 
Zero
Very High
Oncopeptides is selling for under 5.28 as of the 28th of March 2024; that is -20.72 percent down since the beginning of the trading day. The stock's last reported lowest price was 5.14. Oncopeptides has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Oncopeptides AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of June 2022 and ending today, the 28th of March 2024. Click here to learn more.
Oncopeptides AB , a pharmaceutical company, develops drugs for the treatment of cancer. The company was founded in 2000 and is headquartered in Stockholm, Sweden. Oncopeptides is traded on Stockholm Stock Exchange in Sweden. The company has 90.37 M outstanding shares. More on Oncopeptides AB

Moving against Oncopeptides Stock

  0.78VOLV-A AB VolvoPairCorr
  0.78VOLV-B AB VolvoPairCorr
  0.77ATCO-B Atlas Copco ABPairCorr
  0.73SEB-A Skandinaviska EnskildaPairCorr
  0.72ATCO-A Atlas Copco ABPairCorr
  0.58SHB-B Svenska HandelsbankenPairCorr
  0.49SHB-A Svenska HandelsbankenPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Oncopeptides Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Oncopeptides' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Oncopeptides or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEOJakob Lindberg
Business ConcentrationHealth Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Oncopeptides AB (ONCO) is traded on Stockholm Exchange in Sweden and employs 40 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 933.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncopeptides's market, we take the total number of its shares issued and multiply it by Oncopeptides's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Oncopeptides AB operates under Biotechnology sector and is part of Health Care industry. The entity has 90.37 M outstanding shares. Oncopeptides AB has accumulated about 747.47 M in cash with (1.52 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Oncopeptides Probability Of Bankruptcy
Ownership Allocation
Oncopeptides AB has a total of 90.37 Million outstanding shares. 30% of Oncopeptides AB outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Oncopeptides Ownership Details

Oncopeptides Stock Price Odds Analysis

Attributed to a normal probability distribution, the odds of Oncopeptides jumping above the current price in 90 days from now is about 87.51%. The Oncopeptides AB probability density function shows the probability of Oncopeptides stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon Oncopeptides has a beta of 0.954. This indicates Oncopeptides AB market returns are related to returns on the market. As the market goes up or down, Oncopeptides is expected to follow. Additionally, oncopeptides AB has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 5.28HorizonTargetOdds Above 5.28
12.43%90 days
 5.28 
87.51%
Based on a normal probability distribution, the odds of Oncopeptides to move above the current price in 90 days from now is about 87.51 (This Oncopeptides AB probability density function shows the probability of Oncopeptides Stock to fall within a particular range of prices over 90 days) .

Oncopeptides AB Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Oncopeptides market risk premium is the additional return an investor will receive from holding Oncopeptides long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Oncopeptides. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Oncopeptides' alpha and beta are two of the key measurements used to evaluate Oncopeptides' performance over the market, the standard measures of volatility play an important role as well.

Oncopeptides Stock Against Markets

Picking the right benchmark for Oncopeptides stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Oncopeptides stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Oncopeptides is critical whether you are bullish or bearish towards Oncopeptides AB at a given time. Please also check how Oncopeptides' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Oncopeptides without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sectors Now

   

Sectors

List of equity sectors categorizing publicly traded companies based on their primary business activities
All  Next Launch Module

Oncopeptides Corporate Directors

Oncopeptides corporate directors refer to members of an Oncopeptides board of directors. The board of directors generally takes responsibility for the Oncopeptides' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Oncopeptides' board members must vote for the resolution. The Oncopeptides board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

How to buy Oncopeptides Stock?

Before investing in Oncopeptides, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Oncopeptides. To buy Oncopeptides stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Oncopeptides. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Oncopeptides stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Oncopeptides AB stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Oncopeptides AB stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Oncopeptides AB, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.

Already Invested in Oncopeptides AB?

The danger of trading Oncopeptides AB is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Oncopeptides is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Oncopeptides. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Oncopeptides AB is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncopeptides AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Oncopeptides Stock analysis

When running Oncopeptides' price analysis, check to measure Oncopeptides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncopeptides is operating at the current time. Most of Oncopeptides' value examination focuses on studying past and present price action to predict the probability of Oncopeptides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncopeptides' price. Additionally, you may evaluate how the addition of Oncopeptides to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Global Correlations
Find global opportunities by holding instruments from different markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
CEOs Directory
Screen CEOs from public companies around the world
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Please note, there is a significant difference between Oncopeptides' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncopeptides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncopeptides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.